Allena Pharmaceuticals, Inc.
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$11.4M | −$7.5M | −$11.6M | −$8.0M | −$5.5M | −$5.0M |
| Net income | −$11.6M | −$7.6M | −$11.4M | −$35.6M | −$21.6M | −$24.5M |
| Total assets | $34.8M | $38.9M | $34.1M | $65.2M | $96.2M | $49.5M |
| Total liabilities | $15.9M | $16.4M | $16.9M | $15.8M | $13.4M | $13.0M |
| Equity | $18.9M | $22.6M | $17.2M | $49.5M | $82.9M | −$59.3M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 56.9M | 24.7M | 20.8M | 20.7M | 20.7M | 1.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2021- Operating margin
- —
- Net margin
- —
- Return on equity
- −61.7%
- Return on assets
- −33.5%
- Return on capital (ROCE)
- −59.8%
- Liabilities / assets
- 45.7%
- Debt / equity
- 0.84×
- Book value / share
- $0.33
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2021- Altman Z″ (distress)
- -20.80distress
- Accruals / assets
- 97.9%high accruals
- Piotroski F-Score
- 0/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 2 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 14, 2022
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard noticeSep 7, 2022
- Terminated a material agreement · Bankruptcy or receivership · Delisting / listing-standard notice · Director / officer changeSep 2, 2022
- Delisting / listing-standard noticeAug 24, 2022
- Other material eventAug 11, 2022
- Shareholder voteAug 4, 2022
- Entered a material agreement · Unregistered equity sale · Modified shareholder rights · Amended charter or bylaws · Other material eventJul 12, 2022
- Entered a material agreementJul 11, 2022
- Results of operations · Other material eventJul 8, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.